BioMarin/$BMRN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About BioMarin

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Ticker

$BMRN
Primary listing

Industry

Biotechnology

Employees

3,040

ISIN

US09061G1013

BioMarin Metrics

BasicAdvanced
$10B
20.05
$2.70
0.30
-

What the Analysts think about BioMarin

Analyst ratings (Buy, Hold, Sell) for BioMarin stock.

Bulls say / Bears say

BioMarin Pharmaceutical reported a 28% year-over-year revenue growth in Q3 2024, with total revenues reaching $746 million, indicating strong financial performance. (stocktitan.net)
The company's VOXZOGO® (vosoritide) treatment for achondroplasia demonstrated significant height improvements in children, with real-world data showing an average increase of 6.36 cm after 12 months and 11.86 cm after 24 months, supporting its efficacy and market potential. (stocktitan.net)
Analysts have shown confidence in BioMarin's prospects, with Barclays maintaining a 'Buy' rating and setting a price target of $110.00 as of September 2024. (markets.businessinsider.com)
BioMarin's stock reached a new 52-week low of $68.73 in September 2024, reflecting potential investor concerns about the company's valuation. (marketbeat.com)
The company announced a global workforce reduction of approximately 225 employees in September 2024, which may indicate internal challenges or cost-cutting measures that could impact operations. (reuters.com)
BioMarin faces competition from Ascendis Pharma's TransCon CNP, which offers once-weekly dosing for achondroplasia, potentially affecting BioMarin's market share for VOXZOGO®. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.

BioMarin Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BioMarin Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BMRN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs